ClinicalTrials.gg
RecruitingNCT06487078LOREAUpdated Oct 23, 2026

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

An interventional study of Lorlatinib in ALK+ Non-Small-Cell Lung Carcinoma, sponsored by Pfizer. Recruiting at 32 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Pfizer · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 23, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
8th of 27
90 · median 45
Started
2025
with 1 other
No phase
Only one
of the 27
Primary completion
2028-11
later than 12 of 15 live
Registered
22nd of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is the only one with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

03

Conditions studied

  • ALK+ Non-Small-Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply:

  • Patients (male or female) 18 years of age or older at age inclusion
  • Patients with or cytologically confirmed diagnosis of locally advanced or (TNM 8th classification) ALK-positive NSCLC (IHC 3+/FISH positive/transcriptomic method)
  • Complete radiological evaluation has to be performed before the start of lorlatinib by contrast enhanced CT-scan of thorax and upper abdomen and brain MRI, as per routine care
  • Patients with performance status grade 0, 1, or 2

Exclusion Criteria: Participants are excluded from the study if any of the following criteria Apply

  • Evidence of active within the last 2 years prior to inclusion (other than NSCLC, non-melanoma skin cancer, cervical in situ cancer, papillary thyroid cancer, lobular carcinoma in situ/ductal carcinoma in situ (LCIS/DCIS) of the breast, or localized prostate cancer).
  • Patients who have previously received ALK TKI therapy (unless metastatic relapse occurs more than one year after completion of adjuvant therapy).
  • Patients who have previously received systemic NSCLC therapy in metastatic condition.
  • Patients using any of the following food or drugs within 12 days prior to the first dose of lorlatinib:

    • known strong inhibitors
    • known strong CYP3A inducers
    • known P gp substrates with a narrow therapeutic index
  • Patients with any medical or psychiatric condition, or that may, in the investigator's judgment, increase the risk of study participation or make the participant inappropriate for the study.
  • Positive pregnancy test for females of .
  • Breastfeeding and childbearing potential female unwilling/unable to use a highly effective method for the study duration and for at least 35 days after the last dose of lorlatinib
  • Fertile male patients unwilling/unable to use a highly effective method of contraception for the duration of the study and for at least 97 days after the last dose of lorlatinib.
  • Patients participating in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Patients deprived of their liberty, under protective custody or guardianship or unable to provide signed consent.
  • Patients not affiliated to the French social security system.
  • Patients opposed to the collection of their data.
  • Patients willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations including follow-up.
  • Patients judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Lorlatinib

    Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously

    Drug: Lorlatinib

Interventions

  • ALK-positive NSCL treatment

    Also known as: PF-06463922

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time from inclusion to date of disease progression or death of any cause whichever occurs first.

    Time frame: From time of Study Start up to 25 months

Secondary outcomes

  1. Overall Survival (OS)

    Time from inclusion to date of death from any cause.

    Time frame: From time of Study Start up to 25 months

  2. Objective Response Rate (ORR)

    proportion of patients with a Complete Response (CR) or Partial Response (PR) as a best response during the lorlatinib treatment. Responses to treatment will be defined according to investigator

    Time frame: From time of Study Start up to 24 months

  3. Duration of Response (DR)

    time between the first documentation of objective response and the first documentation of disease progression or death from any cause whichever occurred first, for participants with a confirmed objective response of CR or PR.

    Time frame: From time of Study Start up to 24 months

  4. Intracranial Objective Response Rate (IC-ORR)

    proportion of patients with intracranial objective response of complete response (CR) or partial response (PR) as a best response in the subset of patients with at least 1 intracranial lesion assessed by investigator.

    Time frame: From time of Study Start up to 24 months

  5. Intracranial Time to Progression (IC-TTP)

    Time from inclusion to the date of the first documentation of disease progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.

    Time frame: From time of Study Start up to 24 months

  6. Intracranial Duration of Response (IC-DR)

    time from the first documentation of intracranial OR to the first documentation of intracranial progressive disease (PD) or death due to any cause, whichever occurred first for participants with a confirmed objective response of CR or PR assessed by investigator.

    Time frame: From time of Study Start up to 24 months

  7. Duration of Treatment (DT)

    Time between inclusion and last dose of lorlatinib.

    Time frame: From time of Study Start up to 25 months

  8. Proportion of patients with extracranial progression and sites of progression

    Based on Investigator's Assessment

    Time frame: From time of Study Start up to 24 months

  9. Time to Treatment Failure (TTF)

    Time from date of treatment initiation to date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death from any cause whichever occurs first.

    Time frame: From time of Study Start up to 24 months

  10. Adverse Event (AE) as graded by NCI CTCAE v5)

    Frequency of patients experiencing treatment-emergent AEs (TEAEs)

    Time frame: From time of Study Start up to 25 months

  11. Number of Participants With Treatment-Emergent Adverse Events (AEs; Treatment-Related

    Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Treatment-related AEs were determined by investigators.

    Time frame: From time of Study Start up to 25 months

  12. Proportion of patients considered observant to treatment assessed by the compliance questionnaire.

    Self-administered questionnaire that provides a measure of compliance

    Time frame: At the start of cycle (each cyle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and then every 3 months - as long as 48 months

  13. Proportion of patients experiencing a 10-points change from baseline in total score for the EORTC QLQ-C30

    evaluate Health-related Quality of life (HRQoL) of ALK- positive locally advanced or metastatic NSCLC patients treated with lorlatinib in first-line using the EORTC QLQ-C30 questionnaires

    Time frame: At inclusion, At the start of Cycle (each cycle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months

  14. Proportion of patients experiencing a 10-points change from baseline in total score for the EORT QLQ-LC13.

    Evaluate Health-related Quality of life (HRQoL) of ALK- positive locally advanced or metastatic NSCLC patients treated with lorlatinib in first-line using the EORTC QLQ -LC13 questionnaires

    Time frame: At inclusion, At the start of Cycle (each cycle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months

  15. Patient Reported Outcome-informed CNS symptomatic toxicity:

    frequency, severity and/or interference with daily activities, amount, presence/absence according to PRO-CTCAE questionnaires for mood (anxious/discouraged/sad), and attention/memory items (concentration/memory).

    Time frame: At inclusion, At the start of cycle (each cycle is 28 days) Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months

  16. Proportion of patients experiencing grade III toxicities or progression and having an over- or under-exposure to lorlatinib.

    At each time point, a blood sample to provide plasma for determination of the plasma concentrations of lorlatinib.

    Time frame: At baseline, at start of Cycle1Day15 (each cycle is 28 days), Month 3, Month 9 and every 6 months through the end of treatment, at time of first grade III of hyperlipidaemia and CNS toxicity onset, and at progression - as long as 48 months

  17. Proportion of patients experiencing each kind of identified lorlatinib resistance mechanisms

    Plasma samples collected at baseline and end of treatment, analyzed by next-generation sequencing

    Time frame: At baseline and at the date of first documented progression (as long as 48 months)

07

Study locations

23 of 32 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.

Of 360 interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 97. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jul 5, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 France)
  • CHU de Toulouse - Hopital Larrey · Toulouse, France
  • Chru de Nancy-Hopital Brabois · Vandœuvre-lès-Nancy, France
Show 1 removed
  • CHRU de Nancy · Nancy, France
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    2 sites added, 1 site removed
    Show 2 added (2 France)
    • CHU de Toulouse - Hopital Larrey · Toulouse, France
    • Chru de Nancy-Hopital Brabois · Vandœuvre-lès-Nancy, France
    Show 1 removed
    • CHRU de Nancy · Nancy, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06487078
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Jan 20, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion